DFX Intelligence
Data Factory
Reading the graph
Reading the graph
Venture Capital
Los Angeles, CA
We help entrepreneurial life science companies advance groundbreaking technologies and therapies that improve human health.Propel Bio Partners builds ecosysystems to help founders achieve their vision.
Data as of (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built and rebuilt at most every 15 minutes.
| Fund | Vintage | Lifecycle | Form D sold | GAV | LPs |
|---|---|---|---|---|---|
| Propel Bio Partners, L.P. | 2022 | Active deployment | $39.0M | $44.4M | 0 |
| Company | State | Stage | Round size | Partner | Attribution | Observed |
|---|---|---|---|---|---|---|
| EIT Pharma | n/a | Series a | $35.0M | Richard Kayne | Confirmed | Aug 31, 2026 |
| Investor | Co-investor | Shared deals | Shared companies | Last observed | Strength |
|---|---|---|---|---|---|
| Good Ventures | Propel Bio Management, LLC | 1 | 1 | Aug 31, 2026 | One time |
| Propel Bio Management, LLC | Arrowtown | 1 | 1 | Aug 31, 2026 | One time |
Also named here, with no published line of their own (reach them through the firm): Mike Gibbs (Senior Advisor), Suzanne Hendrix (Advisor), Ronald Lee Krall (Senior Advisor), Laurie Heilmann (Venture Partner), Safiya Alavi (Analyst), Armaan Hirani (Data Science Associate), Carol Criner (Advisor), Richard Sudek (Advisor), Leen Kawas (Managing General Partner), XUE Hua (Chief Compliance Officer).
Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan